BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31790828)

  • 1. Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
    Ansari M; Petrykey K; Rezgui MA; Del Vecchio V; Cortyl J; Ralph RO; Nava T; Beaulieu P; St-Onge P; Jurkovic Mlakar S; Huezo-Diaz Curtis P; Uppugunduri CRS; Lesne L; Théoret Y; Chalandon Y; Bartelink IH; Boelens JJ; Bredius RGM; Dalle JH; Lewis V; Kangarloo BS; Peters C; Sinnett D; Bittencourt H; Krajinovic M;
    Biol Blood Marrow Transplant; 2020 May; 26(5):920-927. PubMed ID: 31790828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
    Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.
    Seifert C; Wittig S; Arndt C; Gruhn B
    J Cancer Res Clin Oncol; 2015 May; 141(5):877-85. PubMed ID: 25335953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
    El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
    Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
    Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
    Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.
    Robin S; Hassine KB; Muthukumaran J; Jurkovic Mlakar S; Krajinovic M; Nava T; Uppugunduri CRS; Ansari M
    BMC Mol Cell Biol; 2022 Jan; 23(1):5. PubMed ID: 35062878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
    Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
    Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.
    Huezo-Diaz Curtis P; Uppugunduri CRS; Muthukumaran J; Rezgui MA; Peters C; Bader P; Duval M; Bittencourt H; Krajinovic M; Ansari M
    Pharmacogenomics J; 2018 Jan; 18(1):64-69. PubMed ID: 27779248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
    Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
    Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
    Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
    Chen S; Osborn JD; Chen X; Boyer MW; McDonald GB; Hildebrandt GC
    Int J Hematol; 2015 Dec; 102(6):729-31. PubMed ID: 26497867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome.
    Waespe N; Mlakar SJ; Dupanloup I; Rezgui MA; Bittencourt H; Krajinovic M; Kuehni CE; Nava T; Ansari M
    PLoS One; 2023; 18(4):e0281892. PubMed ID: 37018234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: A single-center experience from the Royal Marsden Hospital, UK.
    Roy Moulik N; Johnson I; Van Bruggen L; Petterson T; Mycroft J; Vaidya SJ
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28677. PubMed ID: 32865880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia.
    Kim H; Lee KH; Sohn SK; Jung CW; Joo YD; Kim SH; Kim BS; Choi JH; Kwak JY; Kim MK; Bae SH; Shin HJ; Won JH; Oh S; Lee WS; Park JH; Yoon SS
    Leuk Res; 2013 Oct; 37(10):1241-7. PubMed ID: 23871157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
    Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
    Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
    Berger K; Schopohl D; Rieger C; Ostermann H
    Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.